Les essais cliniques pour la LMC
Voir le régistre des essais cliniques (en anglais)
ClinicalTrials.gov is a registry of federally and privately supported clinical trials conducted in the United States and around the world. ClinicalTrials.gov gives you information about a trial's purpose, who may participate, locations, and phone numbers for more details. This information should be used in conjunction with advice from health care professionals
http://clinicaltrials.gov/ct/search;jse ... mit=Search
Voir aussi
ESSAIS THERAPEUTIQUES de France intergroupe des Leucémies Myéloïdes Chroniques (FI-LMC)
http://www.lmc-cml.org/fr/page20.xml
-
cousineg
- Messages : 1058
- Enregistré le : lun. août 14, 2006 4:36 am
- Localisation : Montréal (Ar. Saint-Laurent)
-
cousineg
- Messages : 1058
- Enregistré le : lun. août 14, 2006 4:36 am
- Localisation : Montréal (Ar. Saint-Laurent)
Re: Les essais cliniques pour la LMC
State-of-the-Art Treatment for Patients With Chronic Myeloid Leukemia: An Expert Interview With Professor Francois Guilhot, octobre 2007
''Recently reported clinical trials with both imatinib and dasatinib have shown that both agents are effective for treatment of patients with chronic myeloid leukemia (CML). Both are selective inhibitors of Bcr-Abl tyrosine kinase, and imatinib has become the standard of care for treatment of patients with all phases of Philadelphia-positive (Ph+) CML. Recent data from the International Randomized Study of Interferon vs STI571 (IRIS) trial[1,2] show that more than three quarters of those patients are still alive with no treatment-related cardiotoxic side effects. As time progresses, extra mutations may appear, and patients may become resistant to imatinib. Fortunately, new treatments are being developed, such as dasatinib, which is now available in the United States, and nilotinib, which is in late-stage clinical development. However, because neither of these two agents appears to inhibit the Bcr-Abl/T315I mutation, a number of newer agents are being investigated that have activity in the presence of that mutation. ''
Extrait de http://cme.medscape.com/viewarticle/555322?rss
''Recently reported clinical trials with both imatinib and dasatinib have shown that both agents are effective for treatment of patients with chronic myeloid leukemia (CML). Both are selective inhibitors of Bcr-Abl tyrosine kinase, and imatinib has become the standard of care for treatment of patients with all phases of Philadelphia-positive (Ph+) CML. Recent data from the International Randomized Study of Interferon vs STI571 (IRIS) trial[1,2] show that more than three quarters of those patients are still alive with no treatment-related cardiotoxic side effects. As time progresses, extra mutations may appear, and patients may become resistant to imatinib. Fortunately, new treatments are being developed, such as dasatinib, which is now available in the United States, and nilotinib, which is in late-stage clinical development. However, because neither of these two agents appears to inhibit the Bcr-Abl/T315I mutation, a number of newer agents are being investigated that have activity in the presence of that mutation. ''
Extrait de http://cme.medscape.com/viewarticle/555322?rss
-
cousineg
- Messages : 1058
- Enregistré le : lun. août 14, 2006 4:36 am
- Localisation : Montréal (Ar. Saint-Laurent)
Re: Les essais cliniques pour la LMC
CML Combo/Trials...The cure we have been waiting for?
Projet d'essai clinique par Dr Talpaz
...Dr Talpaz is now conducting a Gleevec/Interferon trial and plans a Sprycel/Interferon trial to start in the next three months. He has further plans to combine Interferon with Tasigna and also Bosutinib if it gains FDA approval. Another possible pathway to a cure that he wants to trial is combining TKIs with Hedgehog Pathway Inhibitors. Some of these Hedgehog Pathway Inhibitors target the primitive stem cells that cause CML. ...
Extrait de http://www.newcmldrug.com/Discuss/reply ... eply=25701
Projet d'essai clinique par Dr Talpaz
...Dr Talpaz is now conducting a Gleevec/Interferon trial and plans a Sprycel/Interferon trial to start in the next three months. He has further plans to combine Interferon with Tasigna and also Bosutinib if it gains FDA approval. Another possible pathway to a cure that he wants to trial is combining TKIs with Hedgehog Pathway Inhibitors. Some of these Hedgehog Pathway Inhibitors target the primitive stem cells that cause CML. ...
Extrait de http://www.newcmldrug.com/Discuss/reply ... eply=25701